Avid Bioservices Inc (CDMO)

[mojojojo]

In PII the Bavi arm had a large group of sicker patients (24% according ECOG groups) then what can be enrolled in SUNRISE. So ALSO control arm patients will live longer while Bavi may be doing a BETTER job on less sick patients because it has the time to activate (Bavi seems to have a latency in action).

This subgroup analyses for survival from the bavi phase 2 trial shows that the bavi 3mg/kg arm was more effective for ECOG patient status 0 patients as compared to the control arm. I added the blue vertical line to this chart and it shows that there were only two other subgroups that the bavi arm was better at compared to the control arm.



Here's some commentary from the M. Cobo et al. 2nd line NSCLC trial that discusses ECOG patient status (PS).

...NSCLC patients with PS 2 receiving second-line chemotherapy are probably not the best candidates for a combination schedule, and the ASCO recommendation [38] could be optimally applied in this sub-population. In our trial we found that the median survival in patients with PS 0 was 17.8 months (95% CI, 18.8-21.8%) compared with a median survival of 6.1 months (95% CI,4.1-8.2%) for patients with PS 1 (P=0.0057), and in the Cox regression model, survival was only affected by PS. Most trials that analyze predictive factors like PS have shown that patients with PS 2 have a worse prognosis, and patients with PS 0 or 1 are included within the same subgroup. However, it is important to note the different outcome between this two subpopulations of patients in favor of PS 0.

Here's the subgroup analysis for survival from the phase 3 trial of Pemetrexed vs Docetaxel for previously treated NSCLC patients that shows poor results for ECOG status 2 patients.